Birchview Capital, LP Immunome Inc. Transaction History
Birchview Capital, LP
- $95 Million
- Q2 2025
A detailed history of Birchview Capital, LP transactions in Immunome Inc. stock. As of the latest transaction made, Birchview Capital, LP holds 60,000 shares of IMNM stock, worth $1 Million. This represents 0.59% of its overall portfolio holdings.
Number of Shares
60,000Holding current value
$1 Million% of portfolio
0.59%Shares
1 transactions
Others Institutions Holding IMNM
# of Institutions
149Shares Held
66.7MCall Options Held
44.9KPut Options Held
4.24M-
T. Rowe Price Investment Management, Inc. Baltimore, MD8.28MShares$139 Million0.05% of portfolio
-
Redmile Group, LLC San Francisco, CA4.87MShares$81.6 Million5.51% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct4.69MShares$78.4 Million0.1% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.52MShares$75.7 Million0.0% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA4.08MShares$68.3 Million3.27% of portfolio
About Immunome Inc.
- Ticker IMNM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 12,127,400
- Market Cap $203M
- Description
- Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product ca...